enzh-TWfrdeitjaptrues

Latest Bing Center News

Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed

Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed

A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.

Read more..

Novel Treatments on the Horizon & the Importance of Clinical Trials for Drug Development

Novel Treatments on the Horizon & the Importance of Clinical Trials for Drug Development

Jorge Castillo, MD - The latest information available about potential new treatments for WM, as well as the necessity for patient participation in clinical trials to help move the pipeline along for more novel therapies.

Read more..

Ask The Doctor: Live Q&A - Dr. Tom Hoffmann, Moderating

Ask The Doctor: Live Q&A - Dr. Tom Hoffmann, Moderating

Panelists: Drs. Stephen Ansell, Jorge Castillo, Mary McMaster, Andrew Branagan, Christian Buske, and Steven Treon. A panel of WM experts will answer, and sometimes debate, questions about Waldenstrom macroglobulinemia from the IWMF 2021 Ed Forum audience.

Read more..

A Review of NCCN Guidelines for WM - Steven Treon, MD, PhD

A Review of NCCN Guidelines for WM - Steven Treon, MD, PhD

Dr. Treon will review the NCCN guidelines. NCCN is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. The NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.

Read more..

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

This video webinar was presented by Dr. Andrew Branagan on September 15, 2021 as part of the IWMF's ongoing series of Ed Forum Workshops.

Read more..

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

Approximately 30% of Waldenstrom macroglobulinemia patients are advised to "watch and wait" at time of diagnosis. When should a patient seek treatment?

Read more..

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

As a follow-up to our recent announcement regarding the FDA approval of Zanabrutinib for the treatment of Waldenstrom's Macroglobulinemia (Sept 2, 2021), we are pleased to share this lecture, presented as a webinar on September 24, 2021 by Dr. Steven Treon.

Read more..

Newsweek Names Dana-Farber #3 in the World for Cancer

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber has been named one of the world’s best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings. Dana-Farber was ranked #3 globally. We are the only hospital in New England to be ranked in the top 15 for oncology.

Read more..

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

“The ASPEN trial provided compelling evidence that Brukinsa is a highly active BTK inhibitor in Waldenström’s macroglobulinemia, and compared to the first-generation BTK inhibitor, showed improved tolerability across a number of clinically important side effects. The approval of BRUKINSA provides an important new option for targeted therapy in Waldenström’s macroglobulinemia,” Steven Treon, MD, PhD, director of the Bing Center for Waldenström’s Macroglobulinemia Research at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, said in a statement.

Read more..

LLS National Blood Cancer Conference, September 18, 2021

LLS National Blood Cancer Conference, September 18, 2021

This Blood Cancer Conference is one of many programs developed by The Leukemia & Lymphoma Society to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them. BCC attendees receive the most current information and access to local resources to help navigate and make informed decisions about their treatment and survivorship.

Read more..